New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency

리서치사	Datamonitor
발행일	2009년 05월	상품코드	90340
페이지 정보	79 pages
가격	US $ 5,700 ￦ 6,791,500 PDF by E-mail (Single User License) US $ 14,250 ￦ 16,978,800 PDF by E-mail (Global Site License)

한글목차
영문목차
관련자료

영문목차

Abstract

Introduction

With industry consolidation, the economic downturn, and an increasing threat from generics, pharma companies are coming under greater pressure to fill their pipelines with innovative drugs. However, despite the costs and risks involved in drug development, the pharma industry is finding new ways to streamline the R&D process in an effort to increase efficiency and output.

Scope of this research

Overview of ongoing trends affecting R&D and how these will shape Pharma in the future
R&D Insight from Big Pharma industry executives
Analysis into Pharma' s evolving R&D portfolio between 2006 and 2009, in addition to examination of pipeline M&A and collaborative deals
Case studies of innovative strategies used to maximize R&D productivity

Research and analysis highlights

GlaxoSmithKline, Pfizer and AstraZeneca have the largest preclinical and clinical drug pipelines, each with approximately 200 candidates in development as of March 2009. In terms of volume growth Genentech' s pipeline grew the most in terms of percentage points, almost doubling (up 95%).

Over the period 200609, the average growth per therapy area was 9.4%. In terms of percentage points, the therapy area experiencing the largest growth in pipeline candidates was ophthalmology, while cardiovascular pipelines saw the largest decline, indicative of Pharma' s shift towards niche markets and personalized medicines.

The number of pipeline deals made during 200608 have steadily declined. However, with Biotech finding it hard to fund R&D at present, and with many companies going bankrupt, this will affect Big Pharma in the longer term, which is increasingly downsizing internal research becoming ever reliant on external sources.

Key reasons to purchase this research

Identify R&D trends in today' s pharmaceutical market, and how these affect productivity and return on investment
Understand how a diverse range of strategies can improve R&D productivity and output, and identify how these can best be implemented
Gain insight into how to optimize R&D processes and increase the chance of clinical, and ultimately commercial success

EXECUTIVE SUMMARY

Scope of the report
Methodology for primary and secondary research
- Primary research
- Secondary research
Key findings

OVERVIEW OF TODAY' S R&D LANDSCAPE

Current barriers to R&D optimization
How are pharma companies improving R&D?
- Rivals move to collaborate on R&D
- Two key types of restructuring are available to Pharma
- Refocusing R&D onto biologics will increase efficiency

ANALYSIS OF MEDTRACK PIPELINE AND DEALS DATABASES

Product pipelines grow while deal making activity declines
Analysis of pipeline candidates by therapy area and indication indicate an increased focus on niche markets
- The "big four" tumors are the most popular indications for solid tumors
- Antibacterial, antifungal and antiviral pipelines all demonstrate strong growth
- CNS continues to be a thriving market despite generic competition
- Low levels of innovation hampers the growth of the cardiovascular market
- Ophthalmology had the largest percentage increase in number of drug candidates in clinical development
- Substance abuse saw a steep rise in Phase I drugs, but a decline in other stages of development
- Genentech and Bristol-Myers Squibb have shown a significant jump in pipeline candidates
- Wyeth, GlaxoSmithKline and Johnson & Johnson saw a decline in their number of pipeline candidates
- Daiichi Sankyo boosts its early-stage pipeline through externalizations
- Recent mergers will sharpen R&D structure
Early-stage co-development deals remain the most popular deal type
- Early-stage partnerships are the most popular R&D deal type, but have also seen the steepest decline in recent years
- Co-development deals are most common among earlier-stage companies as well as the top 50 pharma companies

BIBLIOGRAPHY

Publications and online articles
Datamonitor resources

TABLES

Table: Most popular targets in for drugs in development, 2009

FIGURES

Figure: The R&D process is failing somewhere between initial innovation and market approval
Figure: Reasons why pipeline drug candidates are dropped, 2009
Figure: Niche, specialty care markets offer Pharma the greatest growth potential
Figure: Restructuring Big Pharma R&D operations to increase productivity
Figure: Biologics will sharpen the focus of the R&D pipeline
Figure: Biologics are changing the emphasis of the value chain
Figure: The greatest number of pipeline candidates are in preclinical and Phase II development, this corresponds to the stages showing the greatest deal activity, 2006 - Q1 2009
Figure: Number of US licensing deals valued at $0 - 50m entered into by the top 20 pharma companies, Q1 2006 - Q3 2008
Figure: Change (%) in number of pipeline candidates, Q1 2009 versus 2006
Figure: Pipeline candidates by therapy area and indication, 2006 - Q1 2009
Figure: Change in number of pipeline deals by therapy area, 2008 versus 2006
Figure: Number of pipeline candidates versus deals according to therapy area, 2006 - Q1 2009
Figure: Level of R&D interest and unmet need for four solid tumors, 2008
Figure: Clinical unmet needs for the main cardiovascular indications
Figure: Vaccines have high entry barriers for generic companies
Figure: Number of pipeline candidates (preclinical and Phase I - III) and number of deals for the top 10 pharma companies, 2006 - Q1 2009
Figure: Change (%) in number of pipeline candidates, Q1 2009 versus 2006
Figure: Origins of Bristol-Myers Squibb' s product portfolio (2008) and selected key products
Figure: How externalization is supplementing Daiichi Sankyo' s oncology pipeline
Figure: Pfizer, Wyeth and combined Pfizer-Wyeth molecule type and therapy area configurations (% of Rx sales), 2008
Figure: Merck & Co, Schering-Plough and combined Merck-Schering-Plough molecule type configuration (% of Rx sales), 2008
Figure: Trends in sources and partners for pipeline drug deals in the pharma industry, 2006 - 08
Figure: Trends in the source: partner mix for pipeline drug deal-making, 2006 - 08
Figure: The most common pipeline deal types (2006 - 08) have been co-development deals although these are now declining
Figure: Top 10 pipeline drug deal types by partner: source mix, 2006 - 08
Figure: Trends in number of pipeline candidates according to development stage, 2006 - Q1 09
Figure: Trends in number of deals according to development stage, 2006 - 08